Tools
Stock profile

Lantheus Holdings, Inc. (LNTH)

LNTH · Latest close $102.00 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$102.00
As of Nov 18, 2026
Tracked funds holding
2 of 149
2026 Q2 13F filings
Opened / added
1 / 0
vs previous quarter
Trimmed / exited
1
vs previous quarter

Lantheus Holdings, Inc. (LNTH) is held by 2 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions and 1 fund trimming or exiting versus the previous quarter. 0 members of Congress reported 0 purchases vs 2 sales. Latest close $102.00 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Congress
0 buys vs 2 sales
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Deerfield Management · First Eagle Investment Management — 2 tracked funds hold LNTH. See all holders.

Insider and Congress activity

0 members of Congress reported buying (0 purchases vs 2 sales). Politician trading

Often held alongside

IDEXX LABORATORIES INC /DE (IDXX) · Merck & Co., Inc. (MRK) · LINDE PLC (LIN) · ELI LILLY & Co (LLY) · PROCTER & GAMBLE Co (PG) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Deerfield Management0.87%752,999TRIMMED (-9.1%) Q3 filed Nov 16
First Eagle Investment Management<0.01%8,000NEW Q3 filed Nov 10

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -6.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

110.9447.682024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding466 of 8,857 filers
Long-only filers among them464
Change vs 2026 Q1+71 net · 446 entered · 375 exited
Shares reported, all filers75,159,277
Reported value, all filers$8.1B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryIn Vitro & In Vivo Diagnostic Substances (SIC 2835)
Revenue · FY2025$1.5B
Net income · FY2025$233.6M
Total assets · FY2025$2.2B
Shares outstanding65,272,369
Market cap (at latest close)$6.7B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 3, 2026.

Short interest

Shares short · Oct 15, 20263,632,323
Share of shares outstanding5.56%
Days to cover4.48

Shares short at recent settlements — Jul 31, 2026: 6.3M · Aug 14, 2026: 5.1M · Aug 31, 2026: 4.2M · Sep 15, 2026: 4.0M · Sep 30, 2026: 3.8M · Oct 15, 2026: 3.6M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 3, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 24K · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 3, 2026.

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Feb 2, 2026Blanchfield PaulFormer Officer6,713$449.6KFeb 2, 2026SEC filing
Jan 6, 2026Blanchfield PaulFormer Officer7,217$501.8KJan 6, 2026SEC filing
Dec 12, 2025Blanchfield PaulOfficer3,265$218.2KDec 12, 2025SEC filing
Nov 26, 2025Blanchfield PaulFormer Officer11,776$686.7KNov 26, 2025SEC filing
Nov 14, 2025Blanchfield PaulFormer Officer16,530$871.1KNov 14, 2025SEC filing
Aug 13, 2025Blanchfield PaulOfficer3,060$163.9KAug 13, 2025SEC filing
Jun 13, 2025Niedzwiecki DanielOfficer6,000$472.4KJun 13, 2025SEC filing
Jun 9, 2025Marshall Robert J. Jr.Officer39,773$3.2MJun 9, 2025SEC filing
Jun 9, 2025McHugh JulieDirector5,192$423.8KJun 9, 2025SEC filing
Jun 5, 2025Heino Mary AnneDirector26,066$2.0MJun 2, 2025SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 13, 2026Farallon Capital Management, L.L.C.SC 13G/A5,583,4798.6%Jun 30, 2026SEC filing
Jul 31, 2026Vanguard Portfolio ManagementSC 13G3,300,2935.1%Jun 30, 2026SEC filing
May 15, 2026JANUS HENDERSON GROUP PLCSC 13G/A4,774,8417.4%Mar 31, 2026SEC filing
Apr 30, 2026Vanguard Capital ManagementSC 13G3,421,4145.2%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 17, 2026JANUS HENDERSON GROUP PLCSC 13G/A5,707,2478.6%Dec 31, 2025SEC filing
Feb 12, 2026Morgan StanleySC 13G/A1,640,8372.5%Dec 31, 2025SEC filing
Feb 5, 2026Farallon Capital Partners, L.P.SC 13G/A420,5810.6%Dec 31, 2025SEC filing
Nov 14, 2025JANUS HENDERSON GROUP PLCSC 13G/A6,684,7379.8%Sep 30, 2025SEC filing
Nov 12, 2025Farallon Capital Partners, L.P.SC 13G/A278,8960.4%Sep 30, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

0 members of Congress reported buying (0 purchases vs 2 sales).

Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.

Recent activity by member

MemberChamberPartyBuysSellsLatestAmount range
Cisneros, GilbertHouseD02Oct 15, 2026$1,001 - $15,000

Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.

Committee jurisdiction

Industry: In Vitro & In Vivo Diagnostic Substances (SIC 2835). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 91 Lobbying Disclosure Act filings named this company as client, 2010–2026; most common issues: Medicare/Medicaid (48), Health Issues (33), Energy/Nuclear (14).

Federal contracts: $143.5M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$781.6K
FY2022$13.4M
FY2023$26.8M
FY2024$27.3M
FY2025$34.9M
FY2026$40.4M

Largest awards collected

Award IDAgencyAmountStart
36C24622P0024Department of Veterans Affairs$379.8KOct 1, 2021

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Growth — Revenue up every year for 5 straight years

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

Key figures

· Growth — Latest revenue: $1.5B · 5-yr revenue CAGR: 35.4% · Straight growth years: 5

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.45 · Operating cash flow: $390.1M · Net income: $233.6M

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold LNTH — ranked by lift, the co-holding pattern described in Methodology: IDEXX LABORATORIES INC /DE (IDXX) · Merck & Co., Inc. (MRK) · LINDE PLC (LIN) · ELI LILLY & Co (LLY) · PROCTER & GAMBLE Co (PG) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 10, 20268.01 Other EventsSEC filing
Nov 5, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Oct 22, 20268.01 Other EventsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

IDEXX LABORATORIES INC /DE (IDXX) · Track Record: how the signals scored · Practice timing on LNTH

One email a week: the week’s new filings and research. Subscribe free

← LNT  ·  LOAR →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.